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Clinical Factors Associated with Hepatitis A Virus Seropositivity 
in HIV-Infected Adults Living in a Country with an Epidemiologic 
Shift for Hepatitis A Virus Infection
The number of HIV-infected individuals susceptible to Hepatitis A virus (HAV) infection is 
increasing in Korea; however, it has proven difficult to devise a vaccination policy therefore 
because limited seroepidemiologic data exists for them. Accordingly, anti-HAV IgG was 
measured in 188 HIV-infected adults between July 2008 and July 2010. The nadir CD4+ T 
lymphocyte counts were not different between the HAV-positive and –negative groups 
(197 ± 138 vs 202 ± 129, P = 0.821). The only factor independently associated with 
seropositive status was age under 40 yr old (OR 0.017, P < 0.001). Our findings suggest 
that HAV vaccination in HIV-infected adults should be targeted at persons under the age of 
40 yr.
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Worldwide seroprevalence estimates for the hepatitis A virus 
(HAV) suggest that middle-income regions in Asia, Latin Amer-
ica, Eastern Europe, and the Middle East have an intermediate 
or low level of endemicity, but a high proportion of susceptible 
adults due to rapid improvements in sanitation and living stan-
dards (1). Symptomatic HAV infections have been rapidly in-
creasing in these countries (including the Republic of Korea), 
especially in the young adult population (1, 2). HAV infection in 
the young adult population has clinical importance because it 
can cause death by fulminant hepatic failure or acute kidney 
injury (3, 4). 
 Several outbreaks of symptomatic HAV infections have been 
reported among injecting drug users and men who have sex with 
men (MSM) (5, 6). The spread of HAV infection may occur in 
HIV-infected individuals because of shared transmission routes 
(7). Therefore, it is important that a policy for HAV vaccination 
in HIV-infected individuals should be introduced according to 
the seroepidemiological status of each country or region. How-
ever, data for clinical factors associated with HIV seropositivity 
in HIV-infected adults are unclear as to whether a correspond-
ing vaccination policy for non-HIV infected persons can be equal-
ly applied to those infected with HIV. The objective of this study 
was to determine the clinical factors associated with seroposi-
tive status for HAV in HIV-infected adults living in a country with 
recent epidemiological shifts and use them to guide the devel-
opment of vaccination policies.
 Anti-HAV immunoglobulin G (IgG) antibody measurements 
using chemiluminescence immunoassay (VITROS® 3600, Ortho 
Clinical Diagnostics, Wycombe, UK) were taken in 188 HIV-in-
fected adults between July 2008 and July 2010 at Severance Hos-
pital, a 2000-bed, university-affiliated tertiary care hospital in 
Seoul, Republic of Korea. All adults over the age of 20 were eli-
gible, irrespective of age and/or combined antiretroviral treat-
ment (cART). However, HIV-infected individuals with the fol-
lowing conditions were excluded: 1) transfer from other medi-
cal centers, excluding public health centers, and 2) past history 
of adult booster vaccination against HAV (given to those over 
the age of 18). To compare differences in HAV seropositivity ac-
cording to age in the young age group, we analyzed HAV IgG se-
rology data obtained during regular health check-ups that were 
performed in May 2010 in non-HIV-infected health care work-
ers who were less than 35 yr of age. Among the 1,191 health care 
workers, only data from the 816 individuals who had never re-
ceived an adult booster vaccination against HAV were included. 
We identified HAV booster history through the review of medi-
cal records and history taking. This retrospective study received 
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ethical approval from the Institutional Review Board of our in-
stitution, and the need for written informed consent was waived, 
because the design of the study posed no risk to the subjects’ 
rights or welfare. 
 We retrospectively collected epidemiological, immunologi-
cal, and virologic data, concerning mode of transmission, Cen-
ters for Disease Control and Prevention (CDC) categories, CD4+ 
T lymphocyte count and plasma HIV-RNA viral load (VL), through 
a review of the electronic medical records of HIV-infected indi-
viduals. The CDC disease classifications as revised in 1993 were 
used (8). We used the plasma HIV-RNA VL within 6 months be-
fore cART initiation with logarithmic transformation to exclude 
the association between age and VL.
 Data were expressed as numbers (%), mean ± standard devi-
ation (SD) or median (interquartile ranges). We used Student’s 
t-test or Mann-Whitney U test for continuous variables and the 
chi-square test or Fisher’s exact test for categorical/nominal vari-
ables to compare the characteristics between the anti-HAV IgG 
positive and negative groups. Multivariate logistic regression 
analysis was performed using the variables which had P values 
of less than 0.10 in the univariate analysis to identify clinical fac-
tors associated with HAV seropositivity in HIV-infected adults. 
The final regression model was expressed as odds ratios (OR) 
and 95% confidential intervals (CIs). All P  values were two-tailed, 
and P < 0.05 was considered to be statistically significant. SPSS 
18.0 software (SPSS Inc., Chicago, IL, USA) was used for all sta-
tistical analyses. 
 A total of 118 (62.8%) of 188 HIV-infected adults were sero-
positive for HAV. According to age group, the seropositive rates 
were 0% (< 25 yr), 14.3% (≥ 25 and < 30 yr), 37.5% (≥ 30 and 
< 35 yr), 67.6% (≥ 35 and < 40 yr), 97.0% (≥ 40 and < 45 yr), 
and 97.7% (≥ 45 yr). Individuals in the anti-HAV IgG positive 
group were older (44 ± 8 vs 31 ± 6 yr, P < 0.001) than those in 
the negative group. However, the nadir CD4+ T lymphocyte 
counts and log10[plasma HIV-RNA VL within 6 months before 
cART initiation] were similar between the HAV positive and neg-
ative groups (197 ± 138 vs 202 ± 129, P = 0.821, 4.94 [4.36-5.51] 
vs 4.94 [4.35-5.43], P = 0.974, respectively). The rate of cART-na-
ïve individuals was significantly lower in the HAV seropositive 
group (7.6% vs 17.1%, P = 0.045) (Table 1). 
 In the multivariate final logistic regression model, age less 
than 40 yr old (OR 0.017, 95% CI 0.004-0.075, P < 0.001) was the 
only factor independently associated with anti-HAV IgG sero-
positive status (Table 2). 
 The seropositive rate between HIV-infected adults and non-
HIV-infected health care workers was not significantly different 
in either the under 30 age group or the 30-35 age group (8.8% vs 
11.9%, P = 0.786 and 37.5% vs 26.1%, P = 0.183, respectively).  
 The CDC currently recommends vaccination against HAV in 
all HIV-infected adults at a high risk of HAV infection, including 
MSM and intravenous (IV) drug abusers, irrespective of age and 
CD4+ T lymphocyte count (9). However, a few studies have re-
ported that the immunogenecity for the hepatitis A vaccine was 
poor in HIV-infected adults with low CD4+ T lymphocyte count 
(10, 11). Also, the seropositive rate for HAV differs according to 
age and world region in the general global population (1). There-
Table 1. Comparison of clinical characteristics between anti-HAV IgG positive and negative HIV-infected individuals 
Parameters
Total HIV-infected individuals 
(n = 188)
Anti-HAV IgG
  P value*
Positive (n = 118) Negative (n = 70)
Gender, male 179 (95.2) 114 (96.6) 65 (92.9) 0.297†
Age (yr) 39.2 ± 9.8 44.0 ± 8.4 31.0 ± 5.7 < 0.001‡
Mode of transmission 0.410§
   Homosexual
   Heterosexual
   Not clarified
77 (41.0)
38 (20.2)
73 (38.8)
  44 (37.3)
  25 (21.2)
  49 (41.5)
33 (47.1)
13 (18.6)
24 (34.3)
CDC category
   A or B
   C
 
134 (71.3)
  54 (28.7)
 
  83 (70.3)
  35 (29.7)
 
51 (72.9)
19 (27.1)
0.712§
CD4+ T lymphocytes (cells/µL)
   At the HAV IgG measurement
   Nadir
 
  463 ± 238 
  199 ± 134 
 
  480 ± 231
  197 ± 138
 
  434 ± 250
  202 ± 129
 
0.206‡
0.821‡
Plasma HIV-RNA VL (Log10[copies/µL])
   Within 6 months Before cART initiation 
   cART-naïve
 
       4.94 (4.36-5.47)
  21 (11.2)
 
       4.94 (4.36-5.51)
  9 (7.6)
 
     4.94 (4.35-5.43)
12 (17.1)
 
0.974ll
0.045§
The data are expressed as number (percent), mean± standard deviation or median (interquartile ranges). *Comparisons between the anti-HAV IgG positive and negative group; 
†Fisher’s Exact Test; ‡Independent Student’s t-test; §Chi-square tests; llMann-Whitney U test. HAV, hepatitis A virus; IgG, immunoglobulin G; CDC, Centers for Disease Control 
and Prevention; VL, viral load; cART, combined antiretroviral treatment. 
Table 2. Multivariate logistic regression analysis on the clinical factors associated 
with anti-HAV IgG seropositive status in HIV-infected individuals 
Variables Odds ratio 95% CI  P  value
Age, < 40 yr 0.017 0.004-0.075 < 0.001
cART-naïve 0.646 0.217-1.919     0.431
HAV, hepatitis A virus; IgG, immunoglobulin G; CI, confidential interval; cART, combined 
antiretroviral treatment.
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fore, policies for HAV vaccination in HIV-infected adults should 
be tailored according to age, country, and immune status. 
 Ida et al. (12) reported that load and duration of HAV viremia 
was significantly higher and longer in HIV-infected patients than 
in non-HIV-infected patients. In addition, HIV-infected patients 
had lower elevations in alanine aminotransferase than did non-
HIV-infected patients. They suggested that the prolonged HAV 
viremia in HIV-infected patients might cause a long outbreak of 
HAV infection in MSM (12). The prolonged HAV viremia in HIV-
infected patients was described as a case report in 2002 (13). 
Therefore, effective HAV vaccination may prevent the outbreak 
of HAV infection in HIV-infected patients carry out high-risk 
behaviors including MSM or IV drug abusers.
 In the Republic of Korea, as in many developed countries and 
metropolitan communities, symptomatic HAV infections have 
generally shifted from children to older adults (2). Although the 
seroepidemiology of HAV has been reported in various non-
HIV-infected groups, there is little data for HIV-infected adults 
(14-16). 
 This study hypothesized that immune status, evaluated ac-
cording to CD4+ T lymphocyte count, may affect the seroposi-
tivity of HAV IgG in HIV-infected Koreans. In particular, we pre-
sumed that HIV-infected patients with lower CD4+ T lympho-
cyte counts will have a lower seropositivity of HAV IgG. Howev-
er, our results did not reveal an association of CD4+ T lympho-
cyte counts with seropositivity of HAV IgG. 
 In this study, we confirmed that HIV-infected adults who were 
younger, especially less than 35 yr old, had low HAV seropositiv-
ity, similar to the non-HIV-infected general population (2, 15). 
There were no differences in HAV seropositivity in the under 
35 age group, with low rates of less than 50%, among both HIV-
infected and non-HIV-infected adults. Our study revealed that 
HAV seropositivity in HIV-infected Koreans was not associated 
with immunologic and virologic status, which were evaluated 
by nadir CD4+ T lymphocyte counts and plasma HIV-RNA VL 
at 6 months before cART initiation. If HIV-infected adults living 
in countries which have experienced epidemiological shifts 
similar to Republic of Korea are young, clinicians should con-
sider vaccination against HAV. The seropositive rate of HAV and 
the age association in this study were similar to results from a 
Taiwanese study (7). However, HIV transmission due to drug 
use is very rare in the Republic of Korea, unlike Taiwan (17).
 Our findings suggest that, in HIV-infected adults, HAV vacci-
nation should be targeted at younger individuals, especially 
those less than 40 yr of age, irrespective of nadir CD4 + T lym-
phocyte count or plasma HIV-RAN VL before cART initiation. 
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